Skip to content

Affiliation

Instituto Português de Oncologia Francisco Gentil

Country

Portugal

1. Current Status, Position

  • Medical Director and Member of the Board of the Instituto Português de Oncologia Francisco Gentil – Lisboa, Portugal (From February 2012).
  • Alternate member of the Scientific Advice Working Party of the European Medicines Agency (EMA) (From 2008).
  • Member of the Medicines Evaluation Board of the INFARMED (National Institute of Pharmacy and Medicines – Portuguese Drugs Agency) (From 1996).
  • Member of the Protocol Review Committee of the EORTC (From 2001).

2. Education

  • 1978: M.D. University of Lisboa
  • 1983 – 1986: Fellowship Clinical Hematology, Hospitais Civis de Lisboa, Portugal.
  • 1986 – 1988: Fellowship Medical Oncology, Institut Gustave Roussy, Villejuif, France.
  • 1989 – 1991: Clinical Hematologist, Hospitais Civis de Lisboa, Portugal.
  • 1991 – 2001 and 2006 – 2012: Medical Oncologist, Instituto Português de Oncologia Francisco Gentil – Lisboa, Portugal.
  • 2001 – 2005: Medical Director of the Instituto Português de Oncologia Francisco Gentil – Lisboa, Portugal

3. Research Area

João's has focuses his work research on:

  • Clinical care, and development and assessment of chemotherapy and combined treatments in Head and Neck, Gastric, Colorectal, and Breast cancer,
  • Methodology of Clinical Research,
  • Organization of Health Services.
     
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.